Search

Your search keyword '"Cheinquer H"' showing total 187 results

Search Constraints

Start Over You searched for: Author "Cheinquer H" Remove constraint Author: "Cheinquer H"
187 results on '"Cheinquer H"'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

2. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

5. Strategies to manage hepatitis C virus (HCV) disease burden

6. The present and future disease burden of hepatitis C virus (HCV) infection with todayʼs treatment paradigm

7. Historical epidemiology of hepatitis C virus (HCV) in selected countries

10. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

14. Peginterferon alpha-2a plus ribavirin in the retreatment of chronic hepatitis C patients, non-responders and relapsers to previous conventional interferon plus ribavirin therapy: OP-29

15. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

16. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study.

17. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

18. New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society

20. Historical epidemiology of hepatitis C virus (HCV) in selected countries

21. Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

22. Strategies to manage hepatitis C virus (HCV) disease burden

23. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

24. Brazilian Journal of Infectious Diseases

25. 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY

26. The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study

27. Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort

28. 792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY

29. 1098 HCV RNA <15IU/ML AT WEEK 4 IS HIGHLY PREDICTIVE OF SVR AMONG HCV G2/3 PATIENTS RECEIVING PEGINTERFERON ALFA-2A/RBV: FINAL RESULTS FROM POTENTE STUDY

30. 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY

31. 539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

32. 1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

35. 431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS®) PLUS RIBAVIRIN

40. 293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS

41. 1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

42. 292 IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400,000 IU/ML WEIGHING ≥85 kg

Catalog

Books, media, physical & digital resources